search
Back to results

A Novel Wearable Device for the Treatment of Insomnia

Primary Purpose

Insomnia

Status
Not yet recruiting
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
Sleep Wellness Device (BeCurie)
Sponsored by
University of Utah
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Insomnia focused on measuring insomnia, sleep

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Clinically elevated insomnia symptoms as defined by Insomnia Severity Index (ISI) score >=15 Able to read and write in English Smartphone user Exclusion criteria: History of chronic drug or alcohol abuse More than 400mg of caffeine per day Consistent travel across time zones throughout the study period Consistent migraine attacks or headaches Diagnosed sleep disorders other than insomnia Prescribed sleep medications or other treatments for insomnia (e.g. cognitive behavioral therapy) Untreated or unstable psychiatric disorders as defined by a PHQ8 score of greater than 15 Using antipsychotic drugs Pregnant women or lactating women, or have an infant less than 6 months old Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant A history of serious medical conditions (e.g. cancers, consistent hospitalizations) History of allergy or hypersensitivity to any medical device or its components Overnight work >1 shift per month

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Sham Comparator

    Arm Label

    Sleep Wellness Device

    Inactive Sleep Wellness Device

    Arm Description

    The wearable sleep wellness device that contains specially designed coils that generate micro electromagnetic stimulation located in the neckband. It is worn around the neck like headphones for at least 3 hours per day. This device is classified as a low risk wellness device that does not need FDA approval. It can be used by anyone aged 18 and above.

    This device is the sleep wellness device but is running a sham program in the application. The device appears to be activated (lights on) but there is no micro electromagnetic stimulation.

    Outcomes

    Primary Outcome Measures

    Insomnia symptoms
    The insomnia severity index is a self-report item of insomnia symptoms that is well correlated with insomnia diagnoses.

    Secondary Outcome Measures

    Full Information

    First Posted
    July 11, 2023
    Last Updated
    July 11, 2023
    Sponsor
    University of Utah
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT05952297
    Brief Title
    A Novel Wearable Device for the Treatment of Insomnia
    Official Title
    A Novel Wearable Device for the Treatment of Insomnia
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    July 2023
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    August 1, 2023 (Anticipated)
    Primary Completion Date
    January 31, 2024 (Anticipated)
    Study Completion Date
    June 1, 2024 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    University of Utah

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    The purpose of the study is to help determine if a wearable sleep wellness device improves sleep among adults with insomnia. We will enroll a total of 60 participants for this remotly conducted study and randomize 1:1 for treatment and control. Aim 1 of the study is to test the effects of the sleep wellness device compared to a placebo device on sleep after 28 days of use. Aim 2 of the study is to test the longer term effects of the sleep wellness device at 3 month follow-up.
    Detailed Description
    BeCurie is a wearable sleep wellness device that contains specially designed coils that generate micro electromagnetic stimulation located in the neckband. This device is classified as a low risk wellness device that does not need FDA approval. It can be used by anyone aged 18 and above. To test the efficacy of this device, a clinical study entitled "Prospective Observational Double-Blind Placebo-Controlled Randomised Clinical Study to Assess the Stress and Anxiety Improvement with BeCurie" was carried out. (CTRI Registration CTRI/2022/03/041445 )Compared to the placebo group, the treatment group showed improvements in all stress and anxiety-related parameters, showing the effectiveness of the BeCurie device in managing stress and anxiety in individuals with perceived stress and anxiety. Further, no changes were observed in blood profile, biochemistry, and physiological parameters in both groups. No adverse events or side effects were recorded during the study in both placebo and treatment arms, demonstrating BeCurie has been well tolerated. Further testing is warranted to determine whether or not this device has an influence on the quality of sleep of those who wear it. Therefore the goal of this study is to test the effects of this sleep wellness device on sleep quality among adults with elevated insomnia symptoms. This study will test the sleep wellness device compared to a placebo device for changes in sleep over 28 days. Following this 28 day blinded trial, this study will study the effects of the device in an open label, one group study from 28 days to 3 months. This study is fully remote, with no in person office visits. All assessments will occur via web-based surveys, sleep wearable devices (fitbit) and text-message based sleep diaries.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Insomnia
    Keywords
    insomnia, sleep

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 2
    Interventional Study Model
    Parallel Assignment
    Model Description
    For the first 28 days, participants will be randomized 1:1 to intervention vs. placebo. Following 28 days, all devices will be active from day 28 to 3 months.
    Masking
    ParticipantCare ProviderInvestigatorOutcomes Assessor
    Masking Description
    Devices will appear the same but some devices will be placebo and some will be turned on as active. This is turned on remotely. A staff member who is blinded to the study screening and outcomes will conduct the randomization allocation.
    Allocation
    Randomized
    Enrollment
    60 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Sleep Wellness Device
    Arm Type
    Experimental
    Arm Description
    The wearable sleep wellness device that contains specially designed coils that generate micro electromagnetic stimulation located in the neckband. It is worn around the neck like headphones for at least 3 hours per day. This device is classified as a low risk wellness device that does not need FDA approval. It can be used by anyone aged 18 and above.
    Arm Title
    Inactive Sleep Wellness Device
    Arm Type
    Sham Comparator
    Arm Description
    This device is the sleep wellness device but is running a sham program in the application. The device appears to be activated (lights on) but there is no micro electromagnetic stimulation.
    Intervention Type
    Device
    Intervention Name(s)
    Sleep Wellness Device (BeCurie)
    Intervention Description
    This device emits micro electromagnetic stimulation
    Primary Outcome Measure Information:
    Title
    Insomnia symptoms
    Description
    The insomnia severity index is a self-report item of insomnia symptoms that is well correlated with insomnia diagnoses.
    Time Frame
    Baseline to 28 days

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Clinically elevated insomnia symptoms as defined by Insomnia Severity Index (ISI) score >=15 Able to read and write in English Smartphone user Exclusion criteria: History of chronic drug or alcohol abuse More than 400mg of caffeine per day Consistent travel across time zones throughout the study period Consistent migraine attacks or headaches Diagnosed sleep disorders other than insomnia Prescribed sleep medications or other treatments for insomnia (e.g. cognitive behavioral therapy) Untreated or unstable psychiatric disorders as defined by a PHQ8 score of greater than 15 Using antipsychotic drugs Pregnant women or lactating women, or have an infant less than 6 months old Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant A history of serious medical conditions (e.g. cancers, consistent hospitalizations) History of allergy or hypersensitivity to any medical device or its components Overnight work >1 shift per month
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Andrea Baxter, MPH
    Phone
    801-213-5759
    Email
    andrea.baxter@utah.edu
    First Name & Middle Initial & Last Name or Official Title & Degree
    Kelly Baron, PhD
    Phone
    801-581-5585
    Email
    kelly.baron@utah.edu

    12. IPD Sharing Statement

    Learn more about this trial

    A Novel Wearable Device for the Treatment of Insomnia

    We'll reach out to this number within 24 hrs